Zobrazeno 1 - 10
of 187
pro vyhledávání: '"Hilary, Calvert"'
Autor:
Tristin Abair, Hilary Calvert, Nicoletta Colombo, Eric Pujade-Lauraine, Andrew Tutt, Eric Van Cutsem
Publikováno v:
European Medical Journal Oncology, Vol 3, Iss 2, Pp 49-58 (2015)
This engaging symposium focussed on the rationale and current evidence supporting the role for poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition in patients with cancer. The meeting opened with an overview of DNA repair and the biologic
Externí odkaz:
https://doaj.org/article/2dbe38692ac74d62837e561cb1b184f3
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer
Autor:
Hilary Calvert, Chris Twelves, Malcolm Ranson, Ruth Plummer, Scott Fettner, Michael Pantze, Jie Ling, Marta Hamilton, Bert L. Lum, Ashok Rakhit
Publikováno v:
Anti-Cancer Drugs. 25:832-840
In vitro, erlotinib (0-30 µmol/l) and C-labelled midazolam (MDZ) (5 µmol/l) were incubated with human liver microsomes; separately, microsomes were preincubated with erlotinib (10 µmol/l) before the addition of MDZ. Results showed a time-dependent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::208910b37631dd8f1e4265a8b1e7774c
https://doi.org/10.1097/cad.0000000000000099
https://doi.org/10.1097/cad.0000000000000099
Autor:
Hilary Calvert
Publikováno v:
Inorganica Chimica Acta. 498:118987
Following the breakthrough discovery of cisplatin, carboplatin was developed as a less toxic analogue, acting by the same mechanism. Early clinical studies showed that it largely lacked the nephron-, oto-, and neurotoxicity of cisplatin while still h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e80f9a72836b25b89c7223bfc574528f
https://doi.org/10.1016/j.ica.2019.118987
https://doi.org/10.1016/j.ica.2019.118987
Autor:
Hilary Calvert, Jorge Gallo, Diane Wang, Evan A. Mulligan, Ruth Plummer, R. Dewji, Nicola J. Curtin, Richard H. Wilson, Antonello Abbattista, Neil Steven, Mark R. Middleton, Lucy Scott, Paul Lorigan
Publikováno v:
Cancer Chemotherapy and Pharmacology. 71:1191-1199
PURPOSE: poly(ADP ribose) polymerase inhibition has been shown to potentiate the cytotoxicity of DNA damaging agents. A phase I study of rucaparib and temozolomide showed that full-dose temozolomide could be given during PARP inhibition. We report th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24a5f71944f6e4cad781a2c6e8eb29d9
https://doi.org/10.1007/s00280-013-2113-1
https://doi.org/10.1007/s00280-013-2113-1
Autor:
David J. Kerr, Jim Cassidy, Richard Poyner, Leonard W. Seymour, D. R. Ferry, Hilary Calvert, Ruth Duncan, Andreas G. Schätzlein, Stuart Hesslewood, Duncan I. Jodrell, Daniel Rea, Robert Blackie, Adele Robbins, Michael J. Lind, Maggie Whitlock, Donald Bissett, Sally Burtles, Christopher M Boivin, Chris Twelves
Phase I studies of [N-(2-hydroxypropyl)methacrylamide] (HPMA) copolymer-doxorubicin previously showed signs of activity coupled with 5-fold decreased anthracycline toxicity in chemotherapy-refractory patients. Here we report phase H studies using a s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e00789a5e76ad68835ad6a6ec539a96
https://doi.org/10.3892/ijo_00000293
https://doi.org/10.3892/ijo_00000293
Autor:
Christophe, Massard, Jane, Margetts, Nadia, Amellal, Yvette, Drew, Ratislav, Bahleda, Peter, Stephens, Peter, Stevens, Jean Pierre, Armand, Hilary, Calvert, Jean Charles, Soria, Cinthya, Coronado, Carmen, Kahatt, Vicente, Alfaro, Mariano, Siguero, Carlos, Fernández-Teruel, Ruth, Plummer
Publikováno v:
Investigational New Drugs. 31:623-630
PM00104 (Zalypsis®) is a new synthetic alkaloid with potent cytotoxic activity against tumor cell lines. This phase I clinical trial determined the maximal tolerated dose (MTD) and recommended dose (RD) for phase II trials of PM00104 administered as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d67cc753dbf1d5fe9fb57b3f5d79d243
https://doi.org/10.1007/s10637-012-9843-5
https://doi.org/10.1007/s10637-012-9843-5
Publikováno v:
Clinical Investigation. 2:133-138
The Task Force on Methodology for the Development of Innovative Cancer Therapies is an expert forum established to discuss methodological issues in the early clinical development of new molecular-targeted cancer therapeutics. This paper describes the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16bf528dc59a256fa7cb5183de9e3f5c
https://doi.org/10.4155/cli.11.183
https://doi.org/10.4155/cli.11.183
Publikováno v:
European Journal of Cancer. 48:170-178
There has been a significant shift within oncology drug development away from empiric screening of cytotoxic compounds to the era of genomics and molecularly targeted agents. The drug development process is evolving with greater emphasis on proof-of-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ece06e7a94652eb958a80d4e7465e0b
https://doi.org/10.1016/j.ejca.2011.09.024
https://doi.org/10.1016/j.ejca.2011.09.024
Autor:
Alan Hilary Calvert, Elizabeth Ruth Plummer, John Lunec, A R A Razak, A E Quinn, J E Nutt, Fiona Black, K. O'Toole
Publikováno v:
British Journal of Cancer
Background: The standard treatment of choice for malignant pleural mesothelioma is chemotherapy with pemetrexed and platinum, but the clinical outcome is poor. This study investigates the response to pemetrexed in a panel of eight mesothelioma cell l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::865bf1cc13e263f576246e1aea1ee5a1
https://doi.org/10.1038/sj.bjc.6605501
https://doi.org/10.1038/sj.bjc.6605501
Publikováno v:
Hybridoma. 28:415-421
Folate biochemical pathway enzymes such as folylpolyglutamate synthetase (FPGS) are key elements in the folate pathway. The role of FPGS is to add glutamate residues to folates and antifolates, trapping them in the cell and increasing their affinity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acf9d178cf80fea14de7288bf6493be2
https://doi.org/10.1089/hyb.2009.0040
https://doi.org/10.1089/hyb.2009.0040